Oops! This Content is Members Only

Recent Content

• Dr. Morgan on the Differences in Low- and High-Risk Multiple Myeloma
• Dr. Manasanch on Outcomes With Elranatamab in Multiple Myeloma
• Isatuximab Plus Carfilzomib and Dexamethasone Improves PFS in Relapsed/Refractory MM
• Analyzing Survival Outcomes With Ixazomib-Rd in Relapsed/Refractory Multiple Myeloma
• Isatuximab regimen demonstrates PFS benefit in relapsed, refractory multiple myeloma
• Non-invasive, inexpensive analytical tool predicts survival in multiple myeloma
• Elranatamab shows efficacy in relapsed, refractory multiple myeloma
• Lenalidomide and Pomalidomide: Immunomodulating Drug Therapies in Multiple Myeloma
• Neurologic adverse events manageable after CAR-T in multiple myeloma
• COVID-19 Vaccine May Be Less Effective in Patients With Myeloma